IDEXX Laboratories Quarterly Cash Flow Statement
NASDAQ: IDXXHealthcareDiagnostics & ResearchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories free cash flow
In the quarter ended Jun 30, 2026, IDEXX Laboratories generated $347.2 million of operating cash flow and spent $24.6 million on capital expenditures. That left free cash flow of $322.5 million, a free-cash-flow margin of 26.5% of revenue. Free cash flow was up 112.7% from the prior year's $151.6 million.
IDEXX Laboratories returned $346.8 million to shareholders through share repurchases, equal to 108% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 338.41M | 278.45M | 248.19M | 274.61M | 293.99M | 242.68M | 216.15M | 232.84M | 203.30M | 235.58M | 194.52M | 212.23M |
| Net Income growth (YoY) | +15.11% | +14.74% | +14.82% | +17.94% | +44.61% | +3.01% | +11.12% | +9.71% | -9.34% | +10.06% | +12.96% | +17.29% |
| Depreciation & Amortization | 41.05M | 37.68M | 38.72M | 36.63M | 35.77M | 34.06M | 33.71M | 34.13M | 32.19M | 29.90M | 29.74M | 28.98M |
| Stock-Based Compensation | 16.09M | 16.34M | 16.11M | 14.43M | 14.85M | 14.62M | 14.26M | 15.92M | 15.72M | 14.40M | 15.22M | 15.22M |
| Change in Working Capital | -36.80M | -43.35M | 12.39M | 1.09M | -34.27M | -50.36M | 26.66M | 6.69M | -25.92M | -60.00M | 10.24M | 9.72M |
| Operating Cash Flow | 347.16M | 266.25M | 355.76M | 402.34M | 185.74M | 237.96M | 262.02M | 220.08M | 248.31M | 198.59M | 249.85M | 272.43M |
| Capital Expenditures | -24.65M | -31.98M | -29.43M | -31.11M | -34.10M | -30.03M | -29.25M | -28.09M | -33.30M | -30.27M | -32.56M | -34.09M |
| Investing Cash Flow | -25.50M | -33.54M | -28.13M | -44.87M | -33.63M | -29.61M | -39.84M | -27.37M | -32.91M | -106.94M | -30.43M | -27.84M |
| Share Repurchases | -346.80M | -351.04M | -237.77M | -240.19M | -338.11M | -400.89M | -245.99M | -220.76M | -215.52M | -154.76M | -36.85M | -35.07M |
| Debt Repaid | — | — | -75.00M | 0 | — | — | 0 | -75.00M | — | — | -75.00M | 0 |
| Financing Cash Flow | -325.19M | -211.43M | -355.70M | -313.31M | -165.63M | -330.32M | -232.78M | -290.98M | -210.24M | -144.07M | -101.84M | -43.04M |
| Net Change in Cash | -3.60M | 20.46M | -28.10M | 43.57M | 624.00K | -124.30M | -20.37M | -92.95M | 4.16M | -56.50M | 122.24M | 198.86M |
| Free Cash Flow | 322.52M | 234.26M | 326.33M | 371.23M | 151.64M | 207.94M | 232.77M | 191.99M | 215.01M | 168.31M | 217.29M | 238.34M |
This table shows 12 quarterly periods of IDEXX Laboratories's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a cash flow statement?